

# Resource Summary Report

Generated by ASWG on Aug 4, 2026

## Fred Hutchinson Cancer Center Antibody Technology Core Facility

RRID:SCR\_022608

Type: Tool

---

### Proper Citation

Fred Hutchinson Cancer Center Antibody Technology Core Facility (RRID:SCR\_022608)

---

### Resource Information

**URL:** <https://www.fredhutch.org/en/research/shared-resources/core-facilities/antibody-technology.html>

**Proper Citation:** Fred Hutchinson Cancer Center Antibody Technology Core Facility (RRID:SCR\_022608)

**Description:** Designs campaign strategies for generation and identification of novel monoclonal antibody compositions. Our projects encompass range of applications in oncology, viral therapeutics and diagnostics.

**Synonyms:** Fred Hutchinson Cancer Center Antibody Technology, Fred Hutchinson Cancer Center Antibody Technology Shared Resource

**Resource Type:** service resource, access service resource, core facility

**Keywords:** novel monoclonal antibody, oncology, viral therapeutics and diagnostics projects, ABRF, USEDit, NACCSR

**Availability:** Open

**Resource Name:** Fred Hutchinson Cancer Center Antibody Technology Core Facility

**Resource ID:** SCR\_022608

**Alternate IDs:** ABRF\_1538

**Alternate URLs:** [https://coremarketplace.org/RRID:SCR\\_022608/?citation=1](https://coremarketplace.org/RRID:SCR_022608/?citation=1)

**Record Creation Time:** 20220802T050144+0000

**Record Last Update:** 20260804T043744+0000

---

### Ratings and Alerts

No rating or validation information has been found for Fred Hutchinson Cancer Center Antibody Technology Core Facility.

No alerts have been found for Fred Hutchinson Cancer Center Antibody Technology Core Facility.

---

## Data and Source Information

**Source:** [SciCrunch Registry](#)

---

## Usage and Citation Metrics

We found 11 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [ASWG](#) .

Sehgal P, et al. (2025) NRCAM variant defined by microexon skipping is a targetable cell surface proteoform in high-grade gliomas. *Cell reports*, 44(8), 116099.

Contreras M, et al. (2024) Defining the impact of flavivirus envelope protein glycosylation site mutations on sensitivity to broadly neutralizing antibodies. *mBio*, 15(2), e0304823.

Belmont L, et al. (2024) Functional genomics screens reveal a role for TBC1D24 and SV2B in antibody-dependent enhancement of dengue virus infection. *Journal of virology*, 98(11), e0158224.

Belmont L, et al. (2024) Functional genomics screens reveal a role for TBC1D24 and SV2B in antibody-dependent enhancement of dengue virus infection. *bioRxiv : the preprint server for biology*.

Whiteaker JR, et al. (2024) Characterization of an expanded set of assays for immunomodulatory proteins using targeted mass spectrometry. *Scientific data*, 11(1), 682.

Scharffenberger SC, et al. (2024) Targeting RSV-neutralizing B cell receptors with anti-idiotypic antibodies. *Cell reports*, 43(10), 114811.

Lubow J, et al. (2023) Single B cell transcriptomics identifies multiple isotypes of broadly neutralizing antibodies against flaviviruses. *PLoS pathogens*, 19(10), e1011722.

Davidson KA, et al. (2023) Centralspindlin proteins Pavarotti and Tumbleweed along with WASH regulate nuclear envelope budding. *The Journal of cell biology*, 222(8).

Kikawa C, et al. (2023) The effect of single mutations in Zika virus envelope on escape from broadly neutralizing antibodies. *Journal of virology*, 97(11), e0141423.

Kikawa C, et al. (2023) The effect of single mutations in Zika virus envelope on escape from broadly neutralizing antibodies. *bioRxiv : the preprint server for biology*.

Lubow J, et al. (2023) Single B cell transcriptomics identifies multiple isotypes of broadly neutralizing antibodies against flaviviruses. *bioRxiv : the preprint server for biology*.